HLS Therapeutics (HLS) Competitors

Tilray Brands (TSE:TLRY) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.

Does the MarketBeat Community favor TLRY or HLS?

HLS Therapeutics received 34 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 64.15% of users gave HLS Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote.

Company	Underperform	Outperform
Tilray Brands	Outperform Votes No Votes	Underperform Votes 7 100.00%
HLS Therapeutics	Outperform Votes 34 64.15%	Underperform Votes 19 35.85%

Which has higher valuation and earnings, TLRY or HLS?

HLS Therapeutics has lower revenue, but higher earnings than Tilray Brands. HLS Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$610.34M	0.65	-C$183.24M	-C$0.41	-1.50
HLS Therapeutics	C$40.13M	2.58	-C$15.53M	-C$1.00	-4.66

Which has more volatility and risk, TLRY or HLS?

Tilray Brands has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of TLRY or HLS?

11.2% of Tilray Brands shares are owned by institutional investors. Comparatively, 65.2% of HLS Therapeutics shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by company insiders. Comparatively, 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is TLRY or HLS more profitable?

Tilray Brands has a net margin of -30.02% compared to HLS Therapeutics' net margin of -38.70%. Tilray Brands' return on equity of -7.24% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-30.02%	-7.24%	-1.41%
HLS Therapeutics	-38.70%	-25.27%	-2.89%

Do analysts prefer TLRY or HLS?

HLS Therapeutics has a consensus price target of C$4.50, indicating a potential downside of 3.23%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HLS Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media prefer TLRY or HLS?

In the previous week, HLS Therapeutics had 2 more articles in the media than Tilray Brands. MarketBeat recorded 3 mentions for HLS Therapeutics and 1 mentions for Tilray Brands. HLS Therapeutics' average media sentiment score of 1.12 beat Tilray Brands' score of 0.59 indicating that HLS Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HLS Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HLS Therapeutics beats Tilray Brands on 9 of the 17 factors compared between the two stocks.